- Home
- PNI vs AGEN Comparison
PNI vs AGEN Comparison
Compare PNI & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PNI
- AGEN
- Stock Information
- Founded
- PNI 2002
- AGEN 1994
- Country
- PNI United States
- AGEN United States
- Employees
- PNI N/A
- AGEN N/A
- Industry
- PNI Trusts Except Educational Religious and Charitable
- AGEN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PNI Finance
- AGEN Health Care
- Exchange
- PNI Nasdaq
- AGEN Nasdaq
- Market Cap
- PNI 82.8M
- AGEN 96.2M
- IPO Year
- PNI N/A
- AGEN 2000
- Fundamental
- Price
- PNI $7.34
- AGEN $2.92
- Analyst Decision
- PNI
- AGEN Buy
- Analyst Count
- PNI 0
- AGEN 3
- Target Price
- PNI N/A
- AGEN $10.50
- AVG Volume (30 Days)
- PNI 26.4K
- AGEN 551.7K
- Earning Date
- PNI 01-01-0001
- AGEN 11-12-2024
- Dividend Yield
- PNI 4.76%
- AGEN N/A
- EPS Growth
- PNI N/A
- AGEN N/A
- EPS
- PNI N/A
- AGEN N/A
- Revenue
- PNI N/A
- AGEN $160,427,000.00
- Revenue This Year
- PNI N/A
- AGEN N/A
- Revenue Next Year
- PNI N/A
- AGEN $36.13
- P/E Ratio
- PNI N/A
- AGEN N/A
- Revenue Growth
- PNI N/A
- AGEN 59.00
- 52 Week Low
- PNI $6.03
- AGEN $2.50
- 52 Week High
- PNI $7.89
- AGEN $19.69
- Technical
- Relative Strength Index (RSI)
- PNI 34.12
- AGEN 41.32
- Support Level
- PNI $7.32
- AGEN $2.73
- Resistance Level
- PNI $7.65
- AGEN $3.85
- Average True Range (ATR)
- PNI 0.07
- AGEN 0.29
- MACD
- PNI -0.03
- AGEN -0.01
- Stochastic Oscillator
- PNI 0.00
- AGEN 24.03
About PNI Pimco New York Municipal Income Fund II of Beneficial Interest
PIMCO New York Municipal Income Fund II is a closed-end management investment company. Its investment objective is to seek to provide current income exempt from federal, New York State and New York City income tax. The fund portfolio of investments consists of investments in different sectors such as education, transportation, healthcare, and others.
About AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).